Sarepta Therapeutics Inc [SRPT] stock is trading at $136.53, up 1.30%. An important factor to consider is whether the stock is rising or falling in short-term value. The SRPT shares have gain 9.32% over the last week, with a monthly amount glided 13.57%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 21, February 2024, Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results. In a post published today on Yahoo Finance, Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2023 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 28, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2023 financial results and to provide a corporate update.
From an analyst’s perspective:
Sarepta Therapeutics Inc [NASDAQ: SRPT] stock has seen the most recent analyst activity on January 31, 2024, when BMO Capital Markets initiated its Outperform rating and assigned the stock a price target of $170. On December 12, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $109 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $224 on November 21, 2023. Oppenheimer downgraded its rating to a Perform. Cantor Fitzgerald downgraded its rating to Neutral for this stock on October 31, 2023, and downed its price target to $40. In a note dated June 23, 2023, Evercore ISI downgraded an In-line rating on this stock but restated the target price of $139.
Sarepta Therapeutics Inc [SRPT] stock has fluctuated between $55.25 and $159.89 over the past year. Currently, Wall Street analysts expect the stock to reach $148.67 within the next 12 months. Sarepta Therapeutics Inc [NASDAQ: SRPT] shares were valued at $136.53 at the most recent close of the market. An investor can expect a potential return of 8.89% based on the average SRPT price forecast.
Analyzing the SRPT fundamentals
Sarepta Therapeutics Inc [NASDAQ:SRPT] reported sales of 1.10B for the trailing twelve months, which represents a growth of 44.10%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 135.28 points at the first support level, and at 134.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 137.65, and for the 2nd resistance point, it is at 138.76.
Sarepta Therapeutics Inc [SRPT] reported earnings per share of -$0.46 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.23/share, meaning a difference of $0.77 and a surprise factor of 62.60%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.27 per share as compared to estimates of -$1.78 per share, a difference of $1.51 representing a surprise of 84.80%.
Ratios To Look Out For
For context, Sarepta Therapeutics Inc’s Current Ratio is 5.44. On the other hand, the Quick Ratio is 4.90, and the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 11.56, the price to book ratio is 16.71.
Transactions by insiders
Recent insider trading involved Barry Richard, Director, that happened on Nov 03 when 50000.0 shares were purchased. President & CEO, INGRAM DOUGLAS S completed a deal on Nov 03 to buy 25225.0 shares. Meanwhile, Director Chambers Michael Andrew bought 9979.0 shares on Aug 14.
